| 主权项 |
1. A method of treating a disease or disorder mediated by the mGluR2 receptor, said method comprising administering to an individual in need thereof an effective amount of a compound of Formula (V): or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer, wherein: ring A is a moiety selected from the group consisting of: phenyl, —(C5-C6) cycloalkyl, —(C5-C6) cycloalkyenl, -pyridinyl, pyrimidinyl, -pyrazolyl, -thienyl, -thiazolyl, -thiadiazolyl, and -oxazolyl; RQ is selected from the group consisting of —CN and —C(O)NH2; -L- is a bond or a divalent moiety selected from the group consisting of: —(C(R1L)2)p—,—C(O)—, —S(O)—, and —S(O)2—;
p is 1, 2, or 3; each R1L is independently selected from the group consisting of H, —CH3, —CF3, —OH, halogen, -cyclopropyl, —O—CH3, and —O—CF3; R1 is selected from the group consisting of: (1) heterocycloalkyl, heterocycloalkenyl, wherein said heterocycloalkyl and said heterocycloalkenyl are monocyclic or multicyclic ring systems comprising from 3 to 10 ring atoms in which 1, 2, or 3 of the atoms of each said ring system is a ring heteroatom independently selected from the group consisting of N, S, S(O), S(O)2, and O, and wherein each said heterocycloalkyl group and each said heterocycloalkenyl group is unsubstituted or substituted with 1 to 5 groups independently selected from the group consisting of oxo, CN, —OH, halogen, —(C1-C6) alkyl, hydroxy-substituted —(C1-C6) alkyl, —(C1-C6) alkynyl, —(C1-C6) haloalkyl, hydroxy-substituted —(C1-C6) haloalkyl, —O—(C1-C6) alkyl, —(C3-C8) cycloalkyl, -alkyl-cycloalkyl, —CH(OH)cycloalkyl, phenyl, -alkyl-phenyl, monocyclic heteroaryl, -alkyl-monocyclic heteroaryl, —(C3-C8) spirocycloalkyl, —(C3-C8) spiroheterocycloalkyl, —C(O)H, —C(O)OH, —C(O)—(C1-C6) alkyl, —C(O)O(C1-C6) alkyl, —N(R1A)C(O)—(C1-C6) alkyl, —N(R1A)2, —C(O)N(R1A)2, —S(O)2H, —S(O)-phenyl, —S(O)—(C1-C6) alkyl-phenyl, —S(O)2-phenyl, —S(O)2—(C1-C6) alkyl-phenyl, —S(O)2OH, and —S(O)2—(C1-C6) alkyl, wherein each R1A group is independently selected from the group consisting of H and —(C1-C6 alkyl); (2) heteroaryl, wherein said heteroaryl is a monocyclic or multicyclic ring system comprising from 5 to 10 ring atoms in which from 1 to 4 of the atoms of said ring system is a ring nitrogen atom, and wherein said heteroaryl is unsubstituted or substituted with 1 to 5 groups independently selected from the group consisting of oxo, CN, —OH, halogen, —(C1-C6) alkyl, hydroxy-substituted —(C1-C6) alkyl, —(C1-C6) alkynyl, —(C1-C6) haloalkyl, hydroxy-substituted —(C1-C6) haloalkyl, —O—(C1-C6) alkyl, —(C3-C8) cycloalkyl, -alkyl-cycloalkyl, —CH(OH)cycloalkyl, phenyl, -alkyl-phenyl, monocyclic heteroaryl, -alkyl-monocyclic heteroaryl, —(C3-C8) spirocycloalkyl, —C(O)H, —C(O)OH, —C(O)—(C1-C6) alkyl, —C(O)O(C1-C6) alkyl, —N(R1B)C(O)—(C1-C6) alkyl, —N(R1B)2, —C(O)N(R1B)2, —S(O)2H, —S(O)-phenyl, —S(O)—(C1-C6) alkyl-phenyl, —S(O)2-phenyl, —S(O)2—(C1-C6) alkyl-phenyl, —S(O)2OH, and —S(O)2—(C1-C6) alkyl, wherein each R1B group is independently selected from the group consisting of H and —(C1-C6alkyl), with the proviso that R1 is not unsubstituted or substituted triazolyl, and with the further proviso that when R1 is substituted oxadiazolyl, substituted thiazolyl, or substituted thiadiazolyl, then -L- is selected from the group consisting of —(C(R1L)2)p—, and (3) phenyl, wherein said phenyl is unsubstituted or substituted with from 1 to 5 groups independently selected from the group consisting of oxo, CN, —OH, halogen, —(C1-C6) alkyl, —(C1-C6) alkynyl, —(C1-C6) haloalkyl, —O—(C1-C6) alkyl, —(C3-C8) cycloalkyl, -alkyl-cycloalkyl, —CH(OH)cycloalkyl, monocyclic heteroaryl, -alkyl-monocyclic heteroaryl, —(C3-C8) spirocycloalkyl, —C(O)H, —C(O)OH, —C(O)(C1-C6) alkyl, —C(O)O(C1-C6) alkyl, —N(R1C)C(O)—(C1-C6) alkyl, —N(R1C)2, —C(O)N(R1C)2, —S(O)2H, —S(O)-phenyl, —S(O)—(C1-C6) alkyl-phenyl, —S(O)2-phenyl, —S(O)2—(C1-C6) alkyl-phenyl, —S(O)2OH, and —S(O)2—(C1-C6) alkyl, wherein each R1C group is independently selected from the group consisting of H and —(C1-C6 alkyl); (4) —CH2N(R1D)R1E, wherein:
R1D is selected from the group consisting of H, —(C1-C6) alkyl, and —C(O)OR1H; andR1E is selected from the group consisting of —O—(C1-C6) alkyl, heteroalkyl, -alkyl-C(O)N(R1H), and —C(O)OR1H,wherein each R1H is independently selected from the group consisting of H and —(C1-C6) alkyl; and (5) —CH2N(R1F)OR1G, wherein:
R1F is selected from the group consisting of H, —(C1-C6) alkyl, and —C(O)OR1H,wherein each R1H is independently selected from the group consisting of H and —(C1-C6) alkyl; andR1G is selected from the group consisting of H and —(C1-C6) alkyl; n is 0, 1, 2, or 3; each R2 (when present) is independently selected from the group consisting of halogen, —CN, —OH, —(C1-C6) alkyl, —O—(C1-C6) alkyl, —(C1-C6) haloalkyl, —O—(C1-C6) haloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —NH2, —NH(C1-C6)alkyl, —N(C1-C6alkyl)2, —C(O)O(C1-C6) alkyl, and phenyl; and R3 is selected from the group consisting of hydrogen and fluorine. |
